• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖尿病和/或慢性肾脏病患者心血管风险降低——最新进展

Cardiovascular risk reduction in patients with diabetes mellitus and/or chronic kidney disease-an update.

作者信息

Marx-Schütt Katharina

机构信息

Department of Internal Medicine I, University Hospital Aachen, RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany.

出版信息

Herz. 2025 Jun 16. doi: 10.1007/s00059-025-05322-0.

DOI:10.1007/s00059-025-05322-0
PMID:40522356
Abstract

People with diabetes mellitus have a significantly increased risk of developing cardiovascular disease as well as chronic kidney disease. The coexistence of these comorbidities has a significant impact on prognosis. In August 2023, the European Society of Cardiology published new guidelines that include specific recommendations for risk reduction in those affected. The key points of these guidelines, as well as recently published data and their respective practical relevance, are presented in this article.

摘要

糖尿病患者患心血管疾病和慢性肾病的风险显著增加。这些合并症的共存对预后有重大影响。2023年8月,欧洲心脏病学会发布了新指南,其中包括针对受影响人群降低风险的具体建议。本文介绍了这些指南的要点,以及最近公布的数据及其各自的实际意义。

相似文献

1
Cardiovascular risk reduction in patients with diabetes mellitus and/or chronic kidney disease-an update.糖尿病和/或慢性肾脏病患者心血管风险降低——最新进展
Herz. 2025 Jun 16. doi: 10.1007/s00059-025-05322-0.
2
Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.早期转介策略在管理有肾脏疾病标志物的人群中的应用:对临床有效性、成本效益和经济分析证据的系统评价。
Health Technol Assess. 2010 Apr;14(21):1-184. doi: 10.3310/hta14210.
3
Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease.慢性肾脏病多种治疗时代未来肾脏保护试验的设计考量
Nephrol Dial Transplant. 2025 Feb 5;40(Supplement_1):i70-i79. doi: 10.1093/ndt/gfae210.
4
The evolution of type 2 diabetes management: glycemic control and beyond with SGLT-2 inhibitors and GLP-1 receptor agonists.2 型糖尿病管理的演变:SGLT-2 抑制剂和 GLP-1 受体激动剂的血糖控制及其他方面。
J Osteopath Med. 2023 Nov 3;124(3):127-135. doi: 10.1515/jom-2023-0179. eCollection 2024 Mar 1.
5
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理(2025年结石病专家共识)
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
6
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.钠-葡萄糖协同转运蛋白 2 抑制剂或胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病成人患者:临床实践指南。
BMJ. 2021 May 11;373:n1091. doi: 10.1136/bmj.n1091.
7
Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.用于慢性肾病和糖尿病患者的胰高血糖素样肽1(GLP-1)受体激动剂。
Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2.
8
Cardiovascular Disease Risk Estimates in the US CKD Population Using the PREVENT Equation.使用PREVENT方程对美国慢性肾脏病患者群体进行心血管疾病风险评估。
Am J Kidney Dis. 2025 Mar 5. doi: 10.1053/j.ajkd.2025.01.012.
9
Systematic review on urine albumin testing for early detection of diabetic complications.关于尿白蛋白检测用于早期发现糖尿病并发症的系统评价。
Health Technol Assess. 2005 Aug;9(30):iii-vi, xiii-163. doi: 10.3310/hta9300.
10
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline.钠-葡萄糖共转运蛋白 2(SGLT-2)抑制剂治疗慢性肾脏病成人患者:临床实践指南。
BMJ. 2024 Oct 1;387:e080257. doi: 10.1136/bmj-2024-080257.

本文引用的文献

1
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.口服司美格鲁肽与高危2型糖尿病患者的心血管结局
N Engl J Med. 2025 May 29;392(20):2001-2012. doi: 10.1056/NEJMoa2501006. Epub 2025 Mar 29.
2
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.根据SGLT2i使用情况,口服司美格鲁肽与2型糖尿病患者心血管结局:SOUL随机试验的预设分析
Circulation. 2025 Jun 10;151(23):1639-1650. doi: 10.1161/CIRCULATIONAHA.125.074545. Epub 2025 Mar 29.
3
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes.
2型糖尿病患者的强化血压控制
N Engl J Med. 2025 Mar 27;392(12):1155-1167. doi: 10.1056/NEJMoa2412006. Epub 2024 Nov 16.
4
The 'ten commandments' for the 2024 European Society of Cardiology guidelines on elevated blood pressure and hypertension.2024年欧洲心脏病学会高血压和血压升高指南的“十诫”。
Eur Heart J. 2024 Nov 21;45(44):4682-4683. doi: 10.1093/eurheartj/ehae646.
5
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.司美格鲁肽对 FLOW 试验中糖尿病和慢性肾脏病合并心力衰竭结局的影响。
J Am Coll Cardiol. 2024 Oct 22;84(17):1615-1628. doi: 10.1016/j.jacc.2024.08.004. Epub 2024 Aug 30.
6
Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.GLP-1 受体激动剂单药及与 SGLT2 抑制剂联合治疗 2 型糖尿病的心血管、肾脏和安全性结局:系统评价和荟萃分析。
Circulation. 2024 Nov 26;150(22):1781-1790. doi: 10.1161/CIRCULATIONAHA.124.071689. Epub 2024 Aug 30.
7
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.SGLT2 抑制剂联合和不联合胰高血糖素样肽 1 受体激动剂的疗效和安全性: SMART-C 协作荟萃分析随机对照试验。
Lancet Diabetes Endocrinol. 2024 Aug;12(8):545-557. doi: 10.1016/S2213-8587(24)00155-4. Epub 2024 Jul 8.
8
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.司美格鲁肽对 2 型糖尿病患者慢性肾脏病的影响。
N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24.
9
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.司美格鲁肽治疗肥胖相关性心力衰竭合并 2 型糖尿病患者的效果。
N Engl J Med. 2024 Apr 18;390(15):1394-1407. doi: 10.1056/NEJMoa2313917. Epub 2024 Apr 6.
10
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes.2023年欧洲心脏病学会糖尿病患者心血管疾病管理指南
Eur Heart J. 2023 Oct 14;44(39):4043-4140. doi: 10.1093/eurheartj/ehad192.